Latest Breaking News On - Wadet iams - Page 1 : comparemela.com

Patient Experiences Lazarus Effect with NSCLC Treatment

Patient Experiences Lazarus Effect with NSCLC Treatment
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Wadet iamsShreya bhatiaSpencer lessansManuelg cortezVanderbilt ingram cancer centerOncotarget volumeEast asian

Lazarus effect in a patient treated with osimertinib for non-small cell lung cancer with leptomeningeal disease

Lazarus effect in a patient treated with osimertinib for non-small cell lung cancer with leptomeningeal disease
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Shreya bhatiaWadet iamsManuelg cortezSpencer lessansVanderbilt ingram cancer centerEast asian

Continued Investigations are Pertinent for FDA Approvals in the Treatment of Patients With EGFR-mutated NSCLC

Jason Porter, MD, highlights the implications of recent data to emerge following the use of EGFR TKIs in the adjuvant setting, the importance of the potential upcoming FDA approval of osimertinib with chemotherapy in EGFR-positive non–small cell lung cancer, and more.

United statesWadet iamsDanielv wakefieldErina gillaspieNagla abdel karimJason porterVanderbilt ingram cancer centerResearch institute in memphisUniversity of virginiaInstitutional perspectivesLung cancer disease research groupWest cancer centerResearch instituteEgfr tkisAdaura trialInstitutional perspectives in cancer

Dr Iams on the Impact of Adagrasib on Patient Outcomes in KRAS G12C–Mutant NSCLC

Wade T. Iams, MD, discusses the impact of adagrasib on the treatment of patients with KRAS G12C-mutant NSCLC in the second line, as well as its integration into clinical practice.

Wadet iamsVanderbilt ingram cancer centerDivision of hematology oncologyLung cancerOnclive tvPrecision medicine in oncology

Dr Iams on the Effect of the FLAURA2 Trial in EGFR-Mutant NSCLC

Wade T. Iams, MD, discusses the impact of the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer, highlighting the notable improvements in progression-free survival that the approach elicits.

Wadet iamsDivision of hematology oncologyVanderbilt ingram cancer centerInternational associationLung cancerOnclive tvPrecision medicine in oncology